Mackenzie Financial Corp Has $1.96 Million Position in Illumina, Inc. (NASDAQ:ILMN)

Mackenzie Financial Corp cut its position in Illumina, Inc. (NASDAQ:ILMN) by 7.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,095 shares of the life sciences company’s stock after selling 1,059 shares during the quarter. Mackenzie Financial Corp’s holdings in Illumina were worth $1,963,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Annis Gardner Whiting Capital Advisors LLC bought a new stake in Illumina in the 3rd quarter valued at $30,000. VisionPoint Advisory Group LLC boosted its stake in Illumina by 344.6% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock valued at $34,000 after purchasing an additional 193 shares during the period. Riverview Trust Co boosted its stake in Illumina by 203.5% in the 3rd quarter. Riverview Trust Co now owns 261 shares of the life sciences company’s stock valued at $36,000 after purchasing an additional 175 shares during the period. Gradient Investments LLC boosted its stake in Illumina by 375.0% in the 4th quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock valued at $40,000 after purchasing an additional 225 shares during the period. Finally, North Star Investment Management Corp. boosted its stake in Illumina by 183.0% in the 4th quarter. North Star Investment Management Corp. now owns 300 shares of the life sciences company’s stock valued at $42,000 after purchasing an additional 194 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ILMN has been the subject of several recent research reports. Barclays boosted their price target on Illumina from $85.00 to $100.00 and gave the company an “underweight” rating in a research note on Wednesday, April 10th. OTR Global reiterated a “mixed” rating on shares of Illumina in a research report on Wednesday, March 20th. StockNews.com upgraded Illumina from a “hold” rating to a “buy” rating in a research report on Friday, February 16th. HSBC downgraded Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $253.00 target price on shares of Illumina in a research report on Tuesday, April 9th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, Illumina currently has an average rating of “Hold” and a consensus target price of $167.70.

Illumina Price Performance

Shares of ILMN opened at $124.46 on Wednesday. Illumina, Inc. has a 12-month low of $89.00 and a 12-month high of $229.58. The business has a 50-day simple moving average of $132.79 and a two-hundred day simple moving average of $127.58. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.26. The stock has a market cap of $19.82 billion, a PE ratio of -16.96 and a beta of 1.19.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The business had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter in the prior year, the firm earned $0.14 EPS. The business’s revenue for the quarter was up 3.6% compared to the same quarter last year. Analysts anticipate that Illumina, Inc. will post 0.91 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Jacob Thaysen bought 7,330 shares of the stock in a transaction on Thursday, February 22nd. The stock was acquired at an average price of $135.29 per share, with a total value of $991,675.70. Following the acquisition, the chief executive officer now directly owns 14,861 shares in the company, valued at $2,010,544.69. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.17% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.